Ligand Pharmaceuticals Inc. (LGND)
Stock Price:
$83.92 USD
-1.10 (-1.29%)
Updated Oct 26, 2020 1:39 PM EDT - Market open
Key Info
| Market Cap |
1.35B |
| Revenue (ttm) |
126.39M |
| Net Income (ttm) |
-24.66M |
| Shares Out |
16.08M |
| EPS (ttm) |
-1.44 |
| PE Ratio |
n/a |
| Forward PE |
13.40 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 26, 2020 |
| Last Price |
$83.92 |
| Previous Close |
$85.02 |
| Change ($) |
-1.10 |
| Change (%) |
-1.29% |
| Day's Open |
84.49 |
| Day's Range |
82.87 - 85.55 |
| Day's Volume |
241,918 |
| 52-Week Range |
57.24 - 127.80 |
More Stats
| Market Cap |
1.35B |
| Enterprise Value |
998.25M |
| Earnings Date (est) |
Oct 30, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
16.08M |
| Float |
15.43M |
| EPS (basic) |
-0.27 |
| EPS (diluted) |
-1.44 |
| FCF / Share |
1.57 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
1.87% |
| Payout Ratio |
n/a |
| Shares Short |
9.84M |
| Short Ratio |
32.27 |
| Short % of Float |
63.79% |
| Beta |
1.44 |
| PE Ratio |
n/a |
| Forward PE |
13.40 |
| P/FCF Ratio |
53.51 |
| PS Ratio |
10.68 |
| PB Ratio |
1.96 |
| Revenue |
126.39M |
| Operating Income |
-4.45M |
| Net Income |
-24.66M |
| Free Cash Flow |
25.22M |
| Net Cash |
351.03M |
| Net Cash / Share |
21.83 |
| Gross Margin |
41.95% |
| Operating Margin |
-3.52% |
| Profit Margin |
-19.50% |
| FCF Margin |
19.95% |
| ROA |
-0.07% |
| ROE |
-2.84% |
| ROIC |
0.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
6 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$181.67*
(116.48% upside)
Low
146
Current: $83.92
High
229
Target: 181.67
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 120 | 251 | 141 | 109 | 71.91 | 64.54 | 48.97 | 31.39 | 30.04 | 23.54 |
| Revenue Growth | -52.17% | 78.21% | 29.48% | 51.53% | 11.43% | 31.78% | 56.02% | 4.5% | 27.61% | - |
| Gross Profit | 109 | 245 | 136 | 103 | 66.11 | 55.40 | 43.24 | 27.79 | 25.13 | 23.54 |
| Operating Income | 807 | 164 | 68.08 | 43.89 | 27.33 | 19.63 | 14.94 | 0.19 | -2.58 | -31.01 |
| Net Income | 629 | 143 | 12.56 | -1.64 | 230 | 12.02 | 11.42 | -0.53 | 9.72 | -10.37 |
| Shares Outstanding | 19.00 | 21.16 | 21.03 | 20.83 | 19.79 | 20.42 | 20.31 | 19.85 | 19.66 | 19.61 |
| Earnings Per Share | 31.85 | 5.96 | 0.53 | -0.08 | 10.83 | 0.56 | 0.55 | -0.03 | 0.49 | -0.53 |
| EPS Growth | 434.4% | 1024.53% | - | - | 1833.93% | 1.82% | - | - | - | - |
| Operating Cash Flow | -29.34 | 194 | 88.57 | 60.73 | 41.73 | 20.57 | 20.69 | 0.16 | -1.17 | -27.07 |
| Capital Expenditures | -2.55 | -10.89 | 4.90 | -19.55 | -4.12 | -1.01 | -3.95 | -0.58 | 0.45 | -0.73 |
| Free Cash Flow | -31.89 | 183 | 93.47 | 41.19 | 37.60 | 19.56 | 16.74 | -0.41 | -0.72 | -27.80 |
| Cash & Equivalents | 1,070 | 796 | 206 | 144 | 205 | 169 | 17.32 | 15.15 | 18.38 | 24.04 |
| Total Debt | 649 | 636 | 225 | 213 | 202 | 196 | 9.11 | 28.28 | 30.29 | - |
| Net Cash / Debt | 421 | 160 | -18.99 | -68.66 | 3.02 | -27.31 | 8.21 | -13.13 | -11.90 | 24.04 |
| Assets | 1,495 | 1,261 | 671 | 602 | 503 | 258 | 105 | 104 | 121 | 75.56 |
| Liabilities | 728 | 700 | 252 | 231 | 226 | 234 | 55.10 | 77.78 | 104 | 72.06 |
| Book Value | 767 | 561 | 400 | 341 | 237 | 26.32 | 49.61 | 26.49 | 8.19 | -4.85 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Ligand Pharmaceuticals Inc. |
| Country |
United States |
| Employees |
115 |
| CEO |
John L. Higgins |
Stock Information
| Ticker Symbol |
LGND |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: LGND |
| IPO Date |
November 18, 1992 |
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; and Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations. It also offers bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Minnebro for the treatment of hypertension; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.